Business
Strata Critical Medical Hosts 2025 Investor Day; Provides 2026 and Medium-Term Financial Guidance
Event highlights multiple ongoing industry growth catalysts and a range of factors that should enable Strata to grow faster than the overall marketTeam
About this update from Strata Critical Medical, Inc.
[{"type":"text","content":"Event highlights multiple ongoing industry growth catalysts and a range of factors that should enable Strata to grow faster than the overall marketTeam defines roll-up opportunity, acquisition philosophy and priority targets for $200 million of estimated cash available for deployment through 2029New 2026 financial guidance and medium-term financial framework targets a sustained high-teens target CAGR(1) for Adjusted EBITDA on an organic basisAdjusted EBITDA expected to double organically(1) by 2029, before capital deployment NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, \"Strata\" or the \"Company\") is hosting its 2025 Investor Day today at the Nasdaq MarketSite in New York City. The event features presentations by leaders across the business and begins at 2:00pm ET. Key Investment Highlights Market leader with differentiated business model in non-correlated industry with life-saving missionMultiple catalysts driving industry volume growthWell positioned to outgrow the market while expanding marginsTarget for high-teens organic Adjusted EBITDA CAGR(1) in the medium-term, which would result in a doubling of Adjusted EBITDA by 2029Significant roll-up opportunity in fragmented industry with strong balance sheet to execute \"Strata is a market leader in the growing, non-correlated transplant industry in the midst of an incredible transformation, resulting in more organs getting to those who need them and a significantly increased need for clinical and logistical support in this life-saving mission,\" said Will Heyburn Co-CEO and CFO. \"We are well positioned to deliver on these increased demands, and, as such, we are confident in our newly introduced target to organically sustain a high-teens Adjusted EBITDA compound annual growth rate(1) in the medium-term, with further opportunity for significant growth through acquisitions.\" \"Our integrated end to end organ recovery platform operates with a highly efficient, localized service model, saving our customers money, and more importantly, enabling faster and more efficient organ recovery processes,\" said Melissa Tomkiel, Co-CEO and General Counsel. \"That's why, for us, acquisitions in this fragmented market aren't just about the attractive financial return, they can also expand our local service delivery area and enable us to provide addit...